WO1995015940A1 - Alpha-quaternary-alpha-amino acids for use as cns agents - Google Patents
Alpha-quaternary-alpha-amino acids for use as cns agents Download PDFInfo
- Publication number
- WO1995015940A1 WO1995015940A1 PCT/GB1994/002690 GB9402690W WO9515940A1 WO 1995015940 A1 WO1995015940 A1 WO 1995015940A1 GB 9402690 W GB9402690 W GB 9402690W WO 9515940 A1 WO9515940 A1 WO 9515940A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- compounds
- optionally substituted
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- -1 carboxy, phosphono Chemical group 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 12
- 125000001424 substituent group Chemical group 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 11
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 5
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- XDENVSFWQSKKLZ-UHFFFAOYSA-N 1,2,4-oxadiazolidine-3,5-dione Chemical compound O=C1NOC(=O)N1 XDENVSFWQSKKLZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 3
- 125000004419 alkynylene group Chemical group 0.000 claims abstract description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940091173 hydantoin Drugs 0.000 claims abstract description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- 125000005841 biaryl group Chemical group 0.000 claims abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 2
- 239000002904 solvent Substances 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- 150000001450 anions Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 3
- 229910052722 tritium Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229910004727 OSO3H Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 1
- 238000000163 radioactive labelling Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 25
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 69
- 229910001868 water Inorganic materials 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 31
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 230000000694 effects Effects 0.000 description 22
- 239000000126 substance Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 230000002461 excitatory amino acid Effects 0.000 description 17
- 239000003257 excitatory amino acid Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 238000010828 elution Methods 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000003456 ion exchange resin Substances 0.000 description 11
- 229920003303 ion-exchange polymer Polymers 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- DDOQBQRIEWHWBT-UHFFFAOYSA-M 2-azaniumyl-4-[hydroxy(oxido)phosphoryl]butanoate Chemical compound [O-]C(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-M 0.000 description 8
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 8
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000018899 Glutamate Receptors Human genes 0.000 description 7
- 108010027915 Glutamate Receptors Proteins 0.000 description 7
- GZOVEPYOCJWRFC-UHFFFAOYSA-N L-trans-alpha-Amino-2-carboxycyclopropaneacetic acid Chemical compound OC(=O)C(N)C1CC1C(O)=O GZOVEPYOCJWRFC-UHFFFAOYSA-N 0.000 description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001095 motoneuron effect Effects 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 102000015404 Amino Acid Receptors Human genes 0.000 description 6
- 108010025177 Amino Acid Receptors Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- AGSVBAIKOLJRNR-BRFYHDHCSA-N (5r)-3,6-dimethoxy-2-methyl-5-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1C AGSVBAIKOLJRNR-BRFYHDHCSA-N 0.000 description 4
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229940078547 methylserine Drugs 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000000273 spinal nerve root Anatomy 0.000 description 4
- ITAMCOCNZJPJDF-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-yloxymethyl-phenoxyphosphinic acid Chemical compound C1=NC2=C(N)N=CN=C2N1CC(C)OCP(O)(=O)OC1=CC=CC=C1 ITAMCOCNZJPJDF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UWCHSDIUMBNDLT-UHFFFAOYSA-L copper;methylsulfanylmethane;dibromide Chemical compound CSC.Br[Cu]Br UWCHSDIUMBNDLT-UHFFFAOYSA-L 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- YFYNOWXBIBKGHB-FBCQKBJTSA-N (1s,3r)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@]1(N)CC[C@@H](C(O)=O)C1 YFYNOWXBIBKGHB-FBCQKBJTSA-N 0.000 description 2
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- UIWJXEAMDJCNOV-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)-2,4,5,6-tetrafluorobenzene Chemical compound FC1=C(F)C(Cl)=C(F)C(CCl)=C1F UIWJXEAMDJCNOV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RQFMUGYVOISIFE-UHFFFAOYSA-N CCOP(=O)c1ccccc1CCBr Chemical compound CCOP(=O)c1ccccc1CCBr RQFMUGYVOISIFE-UHFFFAOYSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- LQBCXNSDCBYQCQ-UHFFFAOYSA-N OS(=O)(=O)S(=O)S(O)(=O)=O Chemical compound OS(=O)(=O)S(=O)S(O)(=O)=O LQBCXNSDCBYQCQ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000001057 ionotropic effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001174 sulfone group Chemical group 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GSFCOAGADOGIGE-BYPYZUCNSA-N (2s)-2-amino-2-methyl-3-phosphonooxypropanoic acid Chemical class OC(=O)[C@](N)(C)COP(O)(O)=O GSFCOAGADOGIGE-BYPYZUCNSA-N 0.000 description 1
- ZSIZRVLBLGCJGS-NSHDSACASA-N (2s)-2-amino-2-methyl-4-phenylphosphanylbutanoic acid Chemical compound OC(=O)[C@](N)(C)CCPC1=CC=CC=C1 ZSIZRVLBLGCJGS-NSHDSACASA-N 0.000 description 1
- 125000005838 1,3-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[*:1] 0.000 description 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YWVIOAPFIVWBAE-UHFFFAOYSA-N 2-(methylamino)-3-phosphonooxypropanoic acid Chemical compound CNC(C(O)=O)COP(O)(O)=O YWVIOAPFIVWBAE-UHFFFAOYSA-N 0.000 description 1
- HHWFSZXANSAMFC-UHFFFAOYSA-N 3-(1,3-oxazol-4-yl)propanoic acid Chemical compound OC(=O)CCC1=COC=N1 HHWFSZXANSAMFC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DNCAZYRLRMTVSF-UHFFFAOYSA-N 4-(1-amino-1-carboxyethyl)benzoic acid Chemical compound OC(=O)C(N)(C)C1=CC=C(C(O)=O)C=C1 DNCAZYRLRMTVSF-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CJOVFAVEUHAJFK-UHFFFAOYSA-N benzyl 3-hydroxy-2-methyl-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=CC=CC=1COC(=O)C(CO)(C)NC(=O)OCC1=CC=CC=C1 CJOVFAVEUHAJFK-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- RVDJLKVICMLVJQ-UHFFFAOYSA-N diethoxy(phenyl)phosphane Chemical compound CCOP(OCC)C1=CC=CC=C1 RVDJLKVICMLVJQ-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229920006226 ethylene-acrylic acid Polymers 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- RWIKCBHOVNDESJ-NSCUHMNNSA-N methyl (e)-4-bromobut-2-enoate Chemical compound COC(=O)\C=C\CBr RWIKCBHOVNDESJ-NSCUHMNNSA-N 0.000 description 1
- RAVVJKCSZXAIQP-UHFFFAOYSA-N methyl 5-bromopentanoate Chemical compound COC(=O)CCCCBr RAVVJKCSZXAIQP-UHFFFAOYSA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000007598 synaptic excitation Effects 0.000 description 1
- 230000009534 synaptic inhibition Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
- C07C309/61—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- This invention relates to novel cx-substituted amino acids, their use as agents influencing the central nervous system (CNS), their preparation, their use as research tools and as pharmaceuticals , pharr.iaceutical compositions containing them and their use in the manufacture ot medicaments for use in methods of treatment practised on the human or animal body.
- CNS central nervous system
- Y is selected from carboxy, phosphono,
- R 13 arsono, -As0 H(OR 13 ) , arsinico, -As0 H( R 13 ) , sulpho, sulphino, sulpheno, -OSO3H , tetrazolyl, 3- hydroxyisoxazole, 1 , 2,4-oxadiazolidin-3, 5-dione and hydantoin
- R 13 is C ⁇ to Cg alkyl, C 2 to Cg alkenyl, C 2 to Cg alkynyl, C3 to Cg cycloalkylene or optionally substituted aryl or aralkyl;
- B is selected from C to Cg alkylene, C3 to Cg cycloalkylene, C to Cg alkenylene and C to Cg alkynylene optionally chain substituted and optionally substituted on the chain;
- Q is selected from carboxy, C j to Cg alkoxycarbonyl and hydroxamic acid
- R 10 is selected from Cj to Cg alkyl, C to Cg alkenyl,
- R and R 12 are the same or different and are selected from hydrogen, C ⁇ to Cg alkyl, C 2 to Cg alkenyl, C 2 to
- Optional chain substituents in B include one or more of N-H, N-Cj to Cg alkyl, N-C to Cg alkenyl,, N-C to Cg alkynyl, N-Cj to Cg acyl, S, SO, S0 2 , CO or O.
- Optional substituents on chain B and on the aromatic rings specified for Y R 10 ⁇ 11 and R 12 include one or more of C ⁇ to Cg alkyl, C to Cg alkenyl, C to Cg alkynyl, halo, nitro, azido, hydroxy, cyano, ketoalkyl, ketoaryl, carboxy, alkoxycarbonyl, haloalkyl, sulpho, sulphoxide, sulphone, phosphono, tetrazolyl, te trazoly lalky 1 , haloalkenyl, aryl or heteroaryl optionally substituted on the aromatic ring or rings by one or more halo, nitro or hydroxy groups , C i to Cg alkoxy, haloalkoxy, arylalkoxy and haloaralkoxy.
- B is C3 to Cg cycloalkylene or C ⁇ to Cg alkylene.
- Suitable cycloalkylene groups include 1, 2-cyclopropylene, 1,2- or 1, 3-cyclobutylene, 1, 2 - or 1 , 3-cyclopentylene and 1,2-, 1,3- or 1,4- cyclohexylene.
- Y is carboxy, phosphono, - P0 H(OR 13 ) , phosphinico , -P0 2 H ( R 13 ) , -OPO3H2 or -OP0 2 H(OR 13 ) and it has been found that compounds with particularly effective activity are those in which Y is phosphono, -P0 2 H(OR 13 ) , -OP0 2 H(OR 13 ) or -As0 2 H(OR 13 ) .
- Q is preferably carboxy
- R 1 ⁇ is Ci to Cg alkyl or benzyl and R 1 and R 12 are both hydrogen.
- alkyl alkenyl and alkynyl
- alkyl alkenyl and alkynyl
- alkynyl alkynyl
- reference to individual alkyl groups such as “propyl” are specific for the straight-chain version only and references to individual branched chain alkyl groups such as “isopropyl” are specific f r the branched- chain version only.
- An analagous convention applies to other generic term .
- the stereochemistry at asymmetric carbon atom C* in formula I may be in predominantly or substantially completely the (S) or (R) enantiomeric forms or may be a racemic mixture.
- the invention includes any optically active or racemic form which may influence the activity of receptor sites in the CNS. According to the present invention there is also provided the first pharmaceutical use of the compounds of formula I.
- Certain representatives of the compounds of the invention influence the CNS to enhance its electrical activity while others depress central nervous electrical activity.
- Substances of the invention which enhance the electrical activity of the CNS may directly activate or potentiate the activity of excitatory amino acid (EAA) receptors, particularly by interaction with one or more EAA receptors of the etabotropic type known as metabotropic gluta ate receptors (mGluRs).
- EAA excitatory amino acid
- mGluRs metabotropic gluta ate receptors
- Compounds which act at these receptors are useful as research tools for investigating mechanisms of central nervous function, and also, as an aid to the isolation and chemical characterization of excitatory amino acid receptors (for example, by incorporation into affinity chromatography support materials).
- These compounds may also be useful as therapeutic drugs to enhance electrical activity of the CNS in pathological conditions where such activity is depressed.
- Other examples depress the electrical activity of the central nervous system either by blocking post- synaptic EAA receptors or by activating presynaptic EAA receptors which mediate a reduction of synaptic excitatory activity.
- Substances of the application that block post-synaptic EAA receptors are useful as research tools for investigating central nervous mechanisms, and also as drugs for the treatment of disorders of the CNS due to hyperactivity of the CNS (as in epilepsy and spasticity) and for the treatment of those neurodegenerative disorders of the CNS which are due to excessive activation of EAA receptors as is known to occur in ischaemic conditions such as those arising in stroke, heart failure, traumatic head or spinal injury, or which are due to ingestion of certain neurotoxic substances.
- substances with this depressant activity include those which block the N-methyl-D-aspartate type (NMDA)-type of EAA receptor as well as those that have antagonist action at non-NMDA receptors such as oC-amino- 3- hydroxy-5-methylisoxazole-4-propionic acid (AMPA) or kainate type.
- NMDA N-methyl-D-aspartate type
- AMPA oC-amino- 3- hydroxy-5-methylisoxazole-4-propionic acid
- Examples of the compounds of the invention that depress central nervous activity by activating presynaptic metabotropic glutamate receptors are likewise useful as research tools for investigating mechanisms of CNS activity and as drugs for the treatment of disorders of the CNS which require a depression of the nervous system activity such as in epilepsy, spasticity and other conditions involving hyperactivity of the CNS in whole or in part.
- the stereochemistry of the asymmetric carbon atom denotec. * in formula I is important to the activity observed.
- Antagonism of the activity of post-synaptic NMDA receptors is seen most often in substances in which the stereochemistry is substantially completely of the R configuration.
- An agonist or antagonist action at metabotropic glutamate receptors of either a pre- or post-synaptic location is seen most often in compounds where the stereochemistry is of the S configuration. It is expected, however, that whether a substance is an agonist or antagonist at excitatory amino acid receptors will depend on several features of the molecule simultaneously, as well as on the particular sub-type of excitatory amino acid receptor affected.
- the groups R 10 , R 1 , R 12 and any substituents in or on the chain B may be varied to alter the potency and/or the selectivity in the action of the substance at a particular type or sub-type of EAA receptor and also to affect the hydrophilic/lipophilic balance of the molecule in order to assist absorption from the gut and/or passage from the blood into the central nervous system.
- the substituents on chain B may be groups which have an electron-withdrawing influence on the group Y so as to increase the acidity of this group and so enhance the ability of the substance to bind to EAA receptors.
- the substituents may be independently halogen, nitro, azido, hydroxy, cyano, ketoalkyl, ketoaryl, carboxy, alkoxycarbonyl, haloalkyl, sulpho, sulphoxide, sulphone, phosphono, tetrazolyl, tetrazolylalkyl, alkenyl, haloalkenyl, aryl, heteroaryl, haloaryl, nitroaryl, polynitroaryl, hydroxyaryl, polyhydroxyary1, alkoxy , haloalkoxy, arylalkoxy or haloaralkoxy.
- B is fully saturated or has some degree of unsaturation.
- the compounds may be radiolabelled and unsaturation in the B chain is particularly useful for the introduction of radioisotopes into the compounds.
- radioactivity can be introduced as 125j or another radioisotope of iodine in the B chain or the R 10 , R 11 , and R 12 groups, or (particularly) as tritium, by hydrogenation using tritium of precursor molecules bearing unsaturation in any of the substituent groups or of unsaturation within the B chain or in ring systems, by - 7
- the substances will be useful also for the isolation of receptors from central nervous tissue, for example, by linking the molecules via a spacer molecular chain to an affinity chromatography support material of the sepharose or agarose type.
- the invention provides the compounds bound to an affinity chromatography support, optionally via a spacer arm, for use in the isolation of receptors from central nervous tissue. This can be done by using one or more of the groups in the compounds as a reactive substituent for linking to the spacer arm, which would carry at its other end a group capable of reacting with sepharose, agarose, or like affinity chromatography support material.
- the spacer arm may be substantially as used conventionally in the art, for example, it may be an alkyl, aryl or alkylaralkyl chain of from one to eight carbon atoms in length.
- the compounds of the invention usually contain a centre of asymmetry.
- the compounds of the present invention include both RS mixtures, including racemic mixtures, and compounds in which the carbon atom bearing the BY, R 10 , Q and NR 1:L R 12 substituents is substantially completely in the R configuration or substantially completely in the S configuration.
- the present invention provides a process for preparing a compound of formula I comprising the reaction of a compound of formula L-B-Y with a compound of formula R ⁇ -A, wherein:
- L is a leaving group
- A is a synthetic equivalent of 0 C(NH 2 )(COOH).
- B.Y and R*0 are as defined above in a suitable solvent for the reaction.
- L is selected from halo, para- toluenesulphonyloxy , acetoxy, sulphate, methanesulphonyloxy and benzenesulphonyloxy.
- A is conveniently one of the following:
- Cg alkyl or benzyl and "-A is typically provided as the anion of a metallic salt (such as a lithium, copper or lithium cuprate salt).
- a metallic salt such as a lithium, copper or lithium cuprate salt.
- the reaction may be carried out in anhydrous tetrahydrof uran , optionally with other solvents or co-solvents .
- R ⁇ O-A is optionally purified where desired or necessary, for example, by silica gel chromatography and is converted to a compound of the invention
- the invention also provides a process for preparing the compounds of the invention which comprises the reaction of a compound of formula (Y-B- )COR 10 with a compound of formula R 1:1 -R 12 NH2 + X ⁇ .
- X is an anion
- R11 and R 12 are as defined above, in the presence of a cyanide salt (preferably sodium or potassium cyanide) in a suitable solvent for the reaction.
- a cyanide salt preferably sodium or potassium cyanide
- the reaction may be the well-known Strecker Synthesis in which the solvent for the reaction is water/methanol or water/am onia/methanol, X ⁇ is the anion of a strong acid and the reaction is carried out at room temperature.
- the reaction may be the well-known Bucherer-Berg sythesis in which R11R12NH2 + X ⁇ is ammonium carbonate and the reaction is carried out in the same solvents at 40 to 80 ⁇ C, if necessary, under pressure.
- reaction is followed where desired or necessary by purification, for example, by silica gel chromatography, deprotection, for example, in ⁇ N aqueous hydrochloric acid, and purification for example, by ion-exchange chromatography and then crystallisation from an appropriate solvent.
- purification for example, by silica gel chromatography, deprotection, for example, in ⁇ N aqueous hydrochloric acid, and purification for example, by ion-exchange chromatography and then crystallisation from an appropriate solvent.
- salts of the invention can also be prepared in the form of salts of the basic amino group present in the molecule and here, salts of interest are physiologically acceptable acid addition salts, such as salts with hydrochloric acid, acetic acid, succinic acid, tartaric acid, or citric acid.
- a pharmaceutical composition comprising a compound of formula I as defined above with a pharmaceutically acceptable diluent or carrier.
- the invention also provides a method for the treatment of a disorder of the central nervous system comprising the administration to a patient of the compounds or the compositions of the invention.
- Compounds of the invention act on the central nervous system and may be administered parenterally or orally, for example, intravenously for acute treatment, or subcutaneously or orally for chronic treatment. Compounds of the invention may be 11
- suitable vehicles normally as a preparation of a water-soluble salt, though preparations of low water solubility, possibly in association with physiologically tolerable emulsifying agents, may be used for depot administration.
- the compounds for use in the pharmaceutical compositions may be in the form of prodrugs , for example, so modified that they enter the body in a modified inactive form but are converted to their active form at or before a desired site of the body.
- compounds of the invention have been found to stimulate or antagonize EAA receptors and to stimulate or depress spontaneous and evoked synaptic activity in the central nervous system.
- Amino acid receptors mediate or modulate synaptic excitation and inhibition of many synapses in the brain.
- the compounds of the present invention have been found to stimulate or antagonize EAA receptors and to stimulate or depress spontaneous and evoked synaptic activity in the central nervous system.
- Amino acid receptors mediate or modulate synaptic excitation and inhibition of many synapses in the brain.
- the compounds of formula I have one or more of the following advantages. Most importantly, they are more potent and/or selective as either agonists or antagonists at metabotropic glutamate receptors than known compounds. Agonists at these receptors are known to facilitate synaptic plasticity mechanisms likely to be important in memory processes. Such compounds may be useful in cognitive enhancers. Antagonists at these receptors depress nociceptive responses and may then be useful as analgesics. Moreover, these substances constitute a group of compounds that are able to affect a greater variety of EAA receptors than known groups of compounds; they also have an improved lipophilic balance allowing for better absorbance at the blood/brain barrier, and they are more useful as research tools than known compounds of similar structure/function.
- the compounds of formula I may provide insights into the existence and role in central nervous function of metabotropic glutamate receptor sub-types, as defined using molecular biology.
- the reaction mixture was added dropwise via a double tip needle to a solution of copper bromide methylsulphide complex (0.26g, 1.25mmol) in t e t rahydrof uran ( 10ml) and dimethylsulphide (2ml) at -78°C.
- the mixture was warmed to -30°C to - 40°C and stirred for 30 min .
- 4- Bromobu taneni tr ile (0.25ml, 2.5mmol ) in tetrahydrof uran (5ml) was then added at -78 °C.
- the reaction mixture was allowed to stir overnight at -78 °C. Next day, the reaction was warmed to room temperature.
- the compounds of the invention have agonist, partial agonist or antagonist action at excitatory amino acid receptors in the central nervous system. There are several types of these receptors, some or 23
- NMDA N-methyl-D-aspartate
- K kainate
- AMPA oxazole- 4 -propionic acid
- other types of excitatory amino acid receptors are also known, including metabotropic glutamate receptors.
- the NMDA, K and AMPA receptors when activated, produce electrochemical changes in neurones which are important in transmission and metabotropic glutamate receptors additionally cause metabolic changes which are impoftant in longer term changes in receptor function. Additionally, recent advances in molecular biology have revealed the existence of sub-types of the main groups of excitatory amino acid receptors described.
- the compounds of the invention have differential actions at these amino acid receptors.
- Compounds which act at amino acid receptors can affect the action of natural amino acid transmitter substances and thereby influence the electrical activity of the central nervous system.
- nerve cells nerve cells
- the substances may be tested on spinal cord neurones, which have similar characteristics to nerve cells in the brain.
- the isolated spinal cord of the 1-5 day old rat is used, and compounds are tested for their ability to affect the activity of spinal neurones induced by amino acids or electrical stimulation of afferent fibres.
- the spinal cord is surgically removed from an anaesthetised rat and is longitudinally hemisected. A dorsal root is placed across a stimulating electrode and a ventral root 24
- NMDA, kainate or AMPA may be used as the standard agonists for ionotropic EAA receptors of the NMDA, K, or AMPA types, and (1S,3R)-1- aminocyclopentane-1,3-dicarboxylate (ACPD) may be used as a standard agonist for a depolarizing type of metabotropic EAA receptor.
- L-2 -Amino-4 - phosphonobutyrate (L-AP4), ( IS,3R)-ACPD, (1S,3S)-ACPD and (2S,3S,4S)- -( carboxycyclopropyl)glycine (L-CCG-I) may be used as standard agonists for one or more type(s) of metabotropic EAA receptor which mediates depression of monosynaptic excitation of motoneurones following dorsal root stimulation.
- Ratio of 2S,rS,2'S : 2S, ⁇ R,2'R is 95:5 (as measured by ⁇ nmr).
- Ratio of 2R, 1'R,2'R : 2R, rS.2'S is 88.5: 1 1.5 (as measured by l H nmr).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95903410A EP0733036A1 (en) | 1993-12-10 | 1994-12-09 | Alpha-quaternary-alpha-amino acids for use as cns agents |
AU12469/95A AU1246995A (en) | 1993-12-10 | 1994-12-09 | Alpha-quaternary-alpha-amino acids for use as cns agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9325368.0 | 1993-12-10 | ||
GB939325368A GB9325368D0 (en) | 1993-12-10 | 1993-12-10 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995015940A1 true WO1995015940A1 (en) | 1995-06-15 |
Family
ID=10746453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/002690 WO1995015940A1 (en) | 1993-12-10 | 1994-12-09 | Alpha-quaternary-alpha-amino acids for use as cns agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0733036A1 (en) |
AU (1) | AU1246995A (en) |
GB (1) | GB9325368D0 (en) |
WO (1) | WO1995015940A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0771196A1 (en) * | 1994-09-08 | 1997-05-07 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5661184A (en) * | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
US5717109A (en) * | 1994-09-08 | 1998-02-10 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5726320A (en) * | 1995-06-29 | 1998-03-10 | Eli Lilly And Company | Preparation of bicyclohexane derivative |
EP0870760A1 (en) * | 1997-04-08 | 1998-10-14 | Lilly S.A. | Cyclopropyl glycine derivatives with pharmaceutical properties |
WO1999003822A1 (en) * | 1997-07-18 | 1999-01-28 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
US5882671A (en) * | 1994-08-12 | 1999-03-16 | Eli Lilly And Company | Anxiolytic agents |
US5906985A (en) * | 1996-08-27 | 1999-05-25 | Eli Lilly And Company Limited | Pharmaceutical compounds |
US5912248A (en) * | 1995-11-16 | 1999-06-15 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5916920A (en) * | 1995-11-16 | 1999-06-29 | Eli Lilly And Company | 3-substituted Bicyclo 3.1.0!hexane-6-carboxylic acids |
US5925782A (en) * | 1994-08-12 | 1999-07-20 | Eli Lilly And Company | Synthetic excitatory amino acids |
US6054448A (en) * | 1996-10-18 | 2000-04-25 | Eli Lilly And Company Limited | 2-amino-2-(3-substituted cyclobutyl) acetic acid derivatives |
WO2001079185A1 (en) * | 2000-04-18 | 2001-10-25 | Kenneth Curry | Novel amino carboxy alkyl derivatives of barbituric acid |
US6376539B1 (en) | 1998-01-17 | 2002-04-23 | Bayer Aktiengesellschaft | Substituted bicyclic lactones |
US6433004B1 (en) | 1998-01-17 | 2002-08-13 | Bayer Aktiengesellschaft | Substituted β,γ-anellated lactones |
US6462074B1 (en) | 1998-01-17 | 2002-10-08 | Bayer Aktiengesellschaft | Substituted α, β-anellated butyrolactones |
US6825211B1 (en) | 1997-07-18 | 2004-11-30 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
WO2007052169A3 (en) * | 2005-10-18 | 2007-10-25 | Centre Nat Rech Scient | Hypophosphorous acid derivatives and their therapeutical applications |
US7612226B2 (en) | 2005-04-28 | 2009-11-03 | Pfizer Inc. | Amino acid derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2658912A (en) * | 1951-12-28 | 1953-11-10 | Merck & Co Inc | Alpha-methyl glutamic acid and salts and process for preparation |
DE2824116A1 (en) * | 1977-06-01 | 1978-12-14 | Merck & Co Inc | ALPHA -FLUOROMETHYL- ALPHA -AMINO- ALCANIC ACIDS |
US4133964A (en) * | 1977-07-01 | 1979-01-09 | Merrell Toraude Et Compagnie | α-Acetylenic derivatives of α-amino acids |
US4260823A (en) * | 1979-07-02 | 1981-04-07 | Merrell Toruade Et Compagnie | α-Acetylenic derivatives of α-amino acids |
EP0418863A2 (en) * | 1989-09-19 | 1991-03-27 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
-
1993
- 1993-12-10 GB GB939325368A patent/GB9325368D0/en active Pending
-
1994
- 1994-12-09 AU AU12469/95A patent/AU1246995A/en not_active Abandoned
- 1994-12-09 WO PCT/GB1994/002690 patent/WO1995015940A1/en not_active Application Discontinuation
- 1994-12-09 EP EP95903410A patent/EP0733036A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2658912A (en) * | 1951-12-28 | 1953-11-10 | Merck & Co Inc | Alpha-methyl glutamic acid and salts and process for preparation |
DE2824116A1 (en) * | 1977-06-01 | 1978-12-14 | Merck & Co Inc | ALPHA -FLUOROMETHYL- ALPHA -AMINO- ALCANIC ACIDS |
US4133964A (en) * | 1977-07-01 | 1979-01-09 | Merrell Toraude Et Compagnie | α-Acetylenic derivatives of α-amino acids |
US4260823A (en) * | 1979-07-02 | 1981-04-07 | Merrell Toruade Et Compagnie | α-Acetylenic derivatives of α-amino acids |
EP0418863A2 (en) * | 1989-09-19 | 1991-03-27 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
Non-Patent Citations (5)
Title |
---|
AEBI J D ET AL: "Enantioselektive alpha-Alkylierung von Aspargin- and Glutaminsäure über Dilithium enolatocarboxylate von 2-[3-Benzoyl-2-(tert-butyl)-1-methyl-5-oxoimidazolidin-4-yl]essigsäure und 3-[3-Benzoyl-2-(tert-butyl)-1-methyl-5-oxoimidazolidin-4-yl]propionsäure", HELV. CHIM. ACTA (HCACAV,0018019X);85; VOL.68 (6); PP.1507-18, EIDG. TECH. HOCHSCH.;LAB. ORG. CHEM.; ZURICH; CH-8092; SWITZ. (CH) * |
BERDICHEVSKY E ET AL: "Kainate, N-methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro", NEUROSCI. LETT. (NELED5,03043940);83; VOL.36 (1); PP.75-80, UNIV. CHILE;FAC. MED.; SANTIAGO; CHILE (CL) * |
HAEUSLER J: "Synthesis von alpha-Methyl-homocysteinthiolacton", MONATSH. CHEM. (MOCMB7,00269247);93; VOL.124 (10); PP.1071-5, UNIV. WIEN;INST. ORG. CHEM.; VIENNA; A-1090; AUSTRIA (AT) * |
KLEINROK Z ET AL: "Preliminary pharmacological investigation on 38 aminophosphonic acids and their derivatives", POL. J. PHARMACOL. PHARM. (PJPPAA,03010244);85; VOL.37 (5); PP.575-84, MED. ACAD.;INST. CLIN. PATHOL.; LUBLIN; 20-090; POL. (PL) * |
ROBINSON M B ET AL: "Displacement of DL-[3H]-2-amino-4-phosphonobutanoic acid ([3H]APB) binding with methyl-substituted APB analogs and glutamate agonists", BIOCHEMISTRY (BICHAW,00062960);85; VOL.24 (10); PP.2401-5, UNIV. MINNESOTA;MED. SCH.; MINNEAPOLIS; 55455; MN; USA (US) * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882671A (en) * | 1994-08-12 | 1999-03-16 | Eli Lilly And Company | Anxiolytic agents |
US5661184A (en) * | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
US5925680A (en) * | 1994-08-12 | 1999-07-20 | Eli Lilly And Company | Synthetic excitatory amino acids |
US5925782A (en) * | 1994-08-12 | 1999-07-20 | Eli Lilly And Company | Synthetic excitatory amino acids |
US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
US5717109A (en) * | 1994-09-08 | 1998-02-10 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP0771196A1 (en) * | 1994-09-08 | 1997-05-07 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP0771196A4 (en) * | 1994-09-08 | 1997-09-03 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
US5726320A (en) * | 1995-06-29 | 1998-03-10 | Eli Lilly And Company | Preparation of bicyclohexane derivative |
US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
US5912248A (en) * | 1995-11-16 | 1999-06-15 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5916920A (en) * | 1995-11-16 | 1999-06-29 | Eli Lilly And Company | 3-substituted Bicyclo 3.1.0!hexane-6-carboxylic acids |
US5906985A (en) * | 1996-08-27 | 1999-05-25 | Eli Lilly And Company Limited | Pharmaceutical compounds |
US6054448A (en) * | 1996-10-18 | 2000-04-25 | Eli Lilly And Company Limited | 2-amino-2-(3-substituted cyclobutyl) acetic acid derivatives |
EP0870760A1 (en) * | 1997-04-08 | 1998-10-14 | Lilly S.A. | Cyclopropyl glycine derivatives with pharmaceutical properties |
ES2131463A1 (en) * | 1997-04-08 | 1999-07-16 | Lilly Sa | Cyclopropyl glycine derivatives with pharmaceutical properties |
US6172058B1 (en) | 1997-04-08 | 2001-01-09 | Lilly, Sa | Compounds with pharmaceutical properties |
WO1999003822A1 (en) * | 1997-07-18 | 1999-01-28 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
US6825211B1 (en) | 1997-07-18 | 2004-11-30 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
US6376532B2 (en) | 1997-07-18 | 2002-04-23 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
US6433004B1 (en) | 1998-01-17 | 2002-08-13 | Bayer Aktiengesellschaft | Substituted β,γ-anellated lactones |
US6376539B1 (en) | 1998-01-17 | 2002-04-23 | Bayer Aktiengesellschaft | Substituted bicyclic lactones |
US6462074B1 (en) | 1998-01-17 | 2002-10-08 | Bayer Aktiengesellschaft | Substituted α, β-anellated butyrolactones |
US6723718B2 (en) | 1998-01-17 | 2004-04-20 | Bayer Aktiengesellschaft | Substituted α, β-anellated butyrolactones |
WO2001079185A1 (en) * | 2000-04-18 | 2001-10-25 | Kenneth Curry | Novel amino carboxy alkyl derivatives of barbituric acid |
US7612226B2 (en) | 2005-04-28 | 2009-11-03 | Pfizer Inc. | Amino acid derivatives |
WO2007052169A3 (en) * | 2005-10-18 | 2007-10-25 | Centre Nat Rech Scient | Hypophosphorous acid derivatives and their therapeutical applications |
JP2009511624A (en) * | 2005-10-18 | 2009-03-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク (セ エン エール エス) | Hypophosphorous acid derivatives and therapeutic uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU1246995A (en) | 1995-06-27 |
GB9325368D0 (en) | 1994-02-16 |
EP0733036A1 (en) | 1996-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995015940A1 (en) | Alpha-quaternary-alpha-amino acids for use as cns agents | |
KR920000897B1 (en) | Process for preparation of 4-substituted piperazine-2-carboxylic acids | |
KR101769999B1 (en) | Nmda receptor modulators and uses thereof | |
DE60119397T2 (en) | "2-oxo-1-pyrrolidine derivatives and their pharmaceutical use" | |
DE69802389T2 (en) | CONNECTIONS USED AS EFFECTORS OF NEUROEXCITATORY AMINO ACID SENSITIVE RECEPTORS OF THE CENTRAL VENEER SYSTEM, THEIR PRODUCTION AND THEIR BIOLOGICAL USE | |
DE69717148T2 (en) | 3-PYRIDYLENE ANTIOMERS AND THEIR USE AS ANALGETICS | |
WO1995015941A1 (en) | Aryl substituted amino acids, cns influencing agents | |
US5202313A (en) | Bilobalide derivatives, their applications and formulations containing them | |
EP0569333B1 (en) | Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids | |
DE69200394T2 (en) | 3-sulfonylamino-2- (1H) -quinolinones and their 7-azaderivate as stimulating amino acid antagonists. | |
KR100422276B1 (en) | Morphine and diamorphine salts of anionic anesthetic analgesic agents in the form of substituted carboxylic acids, methods for their preparation, uses thereof, and formulations comprising these salts | |
JPH08503229A (en) | 2-Substituted morpholine and thiomorpholine derivatives as GABA-B antagonists | |
HU211529A9 (en) | Compounds for the treatment of neurodegenerative disorders | |
DE69413333T2 (en) | Benzospiroalkene derivatives, processes for their preparation and pharmaceutical compositions containing them | |
ZA200506328B (en) | 2-(butyl-1sylfonylamino)-N-Ä1(R)-6methoxy-pyridin-3-yl)-propylÜ-benzamid, the use thereof in the form of drug an pharmaceutical preperations containing said compound | |
AU686722B2 (en) | Heterocyclic compounds | |
JP3023987B2 (en) | (S) -α-phenyl-2-pyridineethanamine (S) -malate and its use as a medicament | |
DE69615845T2 (en) | POLYCYCLIC ALKALOID DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | |
DE69310524T2 (en) | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | |
EP0564658B1 (en) | 2-(2,3-dicarboxycyclopropyl)glycine and method for producing the same | |
US5426114A (en) | ω-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors | |
CN101747253B (en) | Trisubstituted chiral lactam derivative and preparation method and application thereof | |
WO1994022841A1 (en) | Alkylamino substituted triazinediones, triazinemonothiones and triazinedithiones | |
DE69121920T2 (en) | ANTAGONISTS OF IRRITRATING AMINO ACIDS | |
US20060142350A1 (en) | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 656223 Date of ref document: 19960703 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995903410 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995903410 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995903410 Country of ref document: EP |